{"entity":{"id":"nct07259213","kind":"trial","name":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","aka":[],"tldr":"A phase 1/2 trial of 161Tb RAD402 in prostate cancer, run by Radiopharm Theranostics, Ltd, now recruiting.","summary":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC is a phase 1/2 interventional study registered as NCT07259213 by Radiopharm Theranostics, Ltd, with 73 participants planned, started 2026-03-05 and due to reach its primary completion in 2028-11-30. Interventions recorded: 161Tb RAD402.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07259213","url":"https://clinicaltrials.gov/study/NCT07259213"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07259213","phase":"1/2","setting":"A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-Kallikrein-Related Peptidase 3 (KLK3) Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants With Castration-Resistant Prostate Cancer (CRPC)","sponsor":"Radiopharm Theranostics, Ltd","enrolled":73,"outcomes":[]},"route":"/trials/nct07259213/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}